recombinant factor VIIa

Phase 3Small molecule

SSheba Medical Center

recombinant factor VIIa is one of 69 small molecule programs targeting Hemophilia A. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia aActive, not recruiting

Intracerebral HemorrhageRecruiting

SurgeryUnknown status

Hemophilia aPreclinical

Active, not recruiting

Intracerebral HemorrhagePhase 3

Recruiting

SurgeryPreclinical

Unknown status

Competition

Competitive Landscape

36 competitors in Surgery

#DrugCompanyPhaseTrials

Journavx

Vertex Pharmaceuticals

Approved

1 2

Alfenta

Jazz Pharmaceuticals

Approved

1 3

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

3 4

Nubain

AAultman Health Foundation

Approved

2 5

Marinol

Jazz Pharmaceuticals

Phase 3

1 6

Desferal

Jazz Pharmaceuticals

Phase 3

1 7

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

2 8

Cardene

Sun Pharmaceutical Industries, Inc.

Phase 2

2 9

Tukysa

Pfizer

Phase 2

1 10

Senna

MMedtronic - MITG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Recruiting

Hemophilia a

NCT04023019

Phase 3Recruiting

Intracerebral Hemorrhage

NCT07227246

Clinical

Trials by Indication[1]

Blood Loss1 trial

Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn

Completed·UUnited States Army Institute of Surgical Research·Phase 3·NCT00243243·20 enrolled

Hemophilia A1 trial

Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting·EEmory University··NCT04023019·120 enrolled

Surgery1 trial

A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery

Unknown status·SSheba Medical Center·N/A·NCT01538160·15 enrolled

HAE1 trial

Recombinant Factor VII for Intractable Postpartum Haemorrhage

Completed·—··NCT05298826·41 enrolled

Intracerebral Hemorrhage1 trial

Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial - Part 2

Recruiting·JJoseph Broderick, MD·Phase 3·NCT07227246·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for recombinant factor VIIa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant factor VIIa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant factor VIIa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheba Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSheba Medical Center

recombinant factor VIIa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Blood Loss1 trial

Hemophilia A1 trial

Surgery1 trial

HAE1 trial

Intracerebral Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News